JNJ - Johnson & Johnson
| Previous close | 142.49 |
| Open | 142.75 |
| Bid | 142.30 x 800 |
| Ask | 142.34 x 1300 |
| Day's range | 141.43 - 142.87 |
| 52-week range | 109.16 - 157.00 |
| Volume | 2,393,600 |
| Avg. volume | 8,016,630 |
| Market cap | 374.731B |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | 22.18 |
| EPS (TTM) | 6.41 |
| Earnings date | 16 Jul 2020 |
| Forward dividend & yield | 4.04 (2.82%) |
| Ex-dividend date | 22 May 2020 |
| 1y target est | 164.24 |
- Yahoo Finance
Coronavirus update: Florida sees deadliest day yet as US cases spike, economy jitters grow
The U.S. saw yet another day of record coronavirus casualties on Thursday, led mostly by a relentless surge in the stricken Sun Belt region.
- Zacks
Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy?
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
3 Stocks I'll Be Buying When the Market Crashes Again
These three companies have the resources and the positioning to survive the harshest of economic conditions.
- Reuters
Nonprofits urge Johnson & Johnson to halt sales of Baby Powder globally
The groups, which include educational institutions such as Emory University and activist groups such as Greenpeace, among others, also want the company to recall existing inventory in North America. Janette Robinson Flint, the executive director of Black Women for Wellness, said in a statement that J&J's choice to continue marketing baby powder in international markets, often to Black and Brown consumers, contradicts a statement it issued in June committing to fighting racial inequality.
- Yahoo Finance
Coronavirus update: US cases spike above 3M as WHO withdrawal draws more critics
The U.S. topped 3 million coronavirus cases Wednesday after setting a new record of 60,000 daily cases in the previous day.
- Zacks
Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Motley Fool
Is There a Coronavirus Vaccine Yet?
Companies are testing COVID-19 vaccines right now -- if all goes smoothly, more than one may get to market at “warp speed.”
- Zacks
Johnson & Johnson (JNJ) Stock Moves -0.09%: What You Should Know
In the latest trading session, Johnson & Johnson (JNJ) closed at $142.85, marking a -0.09% move from the previous day.
- Zacks
Emergent's (EBS) 5-Year Deal to Back J&J's Coronavirus Vaccine
Emergent BioSolutions (EBS) extends a five-year deal with J&J to provide its CDMO services to produce the drug substance of the latter's COVID-19 vaccine candidate. Shares rise.
- Motley Fool
3 Stocks I'm Never Selling
AWS was already the largest cloud infrastructure platform in the world, and Amazon revealed it was highly profitable -- which could offset the lower margins of its core marketplace business. Locking customers into its Prime ecosystem -- which offered discounts, free shipping, streaming media, and other perks -- further widened its moat against its brick-and-mortar rivals.
- Reuters
Emergent signs five-year deal backing J&J COVID-19 vaccine
Under the deal, starting next year Emergent will provide large-scale manufacturing services to produce the drug substance over five years, with the first two years valued at about $480 million. The news follows a $135 million deal struck by the two companies in April, to use Emergent's manufacturing facilities to speed up the development and production of its vaccine candidate.
- Motley Fool
10 Things to Do When the Stock Market Crashes
In less than five weeks, the benchmark S&P 500 (SNPINDEX: ^GSPC) plunged 34%, representing the fastest bear market descent in history. Of the past eight bear markets, there have been 13 total corrections of at least 10% within the three years following a bear market bottom. This means the typical rise from a bear market bottom features one or two substantive corrections.
- Zacks
Johnson & Johnson Gets European Approval for Ebola Vaccine
J&J (JNJ) gets approval from the European Commission for Ebola vaccine.
- Reuters
Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses
Early signs of the shift came Wednesday, when positive data for one of Pfizer Inc’s COVID-19 vaccine candidates sent shares of the large U.S. drugmaker up more than 3%. Although the news had little effect on shares of Pfizer’s large rivals in the vaccine race, smaller peers Moderna Inc and Inovio Pharmaceuticals Inc, both of which have previously shown promising COVID-19 data of their own, ended down more than 4% and 25%, respectively. For the week so far, shares of bigger players in the vaccine race, such as Johnson & Johnson and Merck , have also outperformed Inovio and Moderna.
- Motley Fool
Will Legal Problems Bankrupt Johnson & Johnson?
A flurry of legal challenges is always a good reason for investors to be wary of a company. Lawsuits related to its talc-based products and the company's role in the opioid crisis present some of the biggest risks to long-term investors. Although J&J may be able to manage those legal challenges today, that doesn't mean it always will.
- Motley Fool
Better Buy: Eli Lilly vs. Johnson & Johnson
As two of the largest healthcare companies in the world, both Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) have a role to play in well-balanced healthcare portfolios. With a profit margin of 23.8%, 15.1% year-over-year quarterly revenue growth, and trailing-12-month revenues of $23.1 billion, Eli Lilly exudes success.
- Motley Fool
Love Dividends? 3 Stocks You Might Want to Buy
A rising dividend stream not only hedges against inflation, it also accelerates payback on investment.
- Motley Fool
This Under-the-Radar Stock Is a Better Way to Bet on Coronavirus Vaccines
Emergent BioSolutions has become the go-to manufacturing partner for companies looking to develop vaccines for the coronavirus.
- Zacks
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
Johnson & Johnson (JNJ) closed the most recent trading day at $139.04, moving +0.89% from the previous trading session.
- Zacks
J&J (JNJ) Discontinues Phase III Study of Stelara for Lupus
Johnson & Johnson (JNJ) discontinues phase III study of Stelara (ustekinumab) in systemic lupus erythematosus.
- Reuters
J&J scraps late-stage study testing Stelara for lupus
Stelara, which blocks two inflammation-causing proteins IL-12 and IL-23, is one of J&J's largest revenue generators, bringing in sales of about $1.82 billion in first quarter this year. The drug is approved in the United States to treat the skin condition scaly plaque psoriasis, a type of arthritis associated with psoriasis and Crohn's disease.
- Reuters
Vaccine makers face biggest medical manufacturing challenge in history
From deploying experts amid global travel restrictions to managing extreme storage conditions, and even inventing new kinds of vials and syringes for billions of doses, the path is strewn with formidable hurdles, according to Reuters interviews with more than a dozen vaccine developers and their backers. Any hitch in an untested supply chain - which could stretch from Pune in India to England's Oxford and Baltimore in the United States - could torpedo or delay the complex process. Col. Nelson Michael, director of the U.S. Army's Center for Infectious Disease Research who is working on the government's "Warp Speed" project to deliver a vaccine at scale by January, said companies usually have years to figure this stuff out.
- Zacks
Appeals Court Rules Against J&J but Cuts Talc- Powder Verdict
J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.
AFP NewsJohnson & Johnson told to pay $2.1 billion over cancer-causing talc powder
A US court has upheld a verdict that talcum powder sold by Johnson & Johnson caused ovarian cancer and ordered the pharmaceutical giant to pay $2.1 billion in damages. The decision by the Missouri Court of Appeals cut by more than half the $4.4 billion a jury had awarded 22 people in 2018. "Because defendants are large, multi-billion-dollar corporations, we believe a large amount of punitive damages is necessary to have an effect in this case," the judgement said.
- Associated Press
Appeals court reduces J&J talc verdict but censures company
A Missouri appeals court has reduced a talcum powder verdict against Johnson & Johnson by more than half, even while ruling that the company knowingly sold a product that caused cancer. In the ruling announced Tuesday, the Eastern District Missouri Court of Appeals rejected the company's request to throw out a St. Louis jury's verdict in 2018 that awarded 22 plaintiffs $4.7 billion in response to claims that Johnson & Johnson’s talcum powder causes ovarian cancer.
